ZOLL Cardiac Management Solutions

LifeVest median Wear Time® is 23.4 hours/day. With a lightweight and breathable design, patients rate the next generation garment even more comfortable. Meet the newest LifeVest: bit.ly/3VxKUoM

We're looking forward to meeting you at #NSN2024 in two weeks and sharing how you can help make a lifesaving impact with your sales career. Apply now and when you're on-site in Houston, stop by Booth 507. Can't make it to the conference? Learn more and apply now: bit.ly/4cT9INq

Are you starting your days doing work you enjoy – and ending them feeling like you’ve made an impact? At ZOLL, we are. You could, too, if you #joinus: bit.ly/3UPrtXU

Take ZOLL out to the ballgame! Some of our Pittsburgh-based employees spent time together outside of the office at a night at the ballpark to watch the Pirates take on the Philadelphia Phillies.

As a leading employer in the Pittsburgh region, ZOLL is invested in supporting our community and creating opportunity. Today, in partnership with 100 Black Men of Western Pennsylvania, we hosted students on-site as part of Infolink-100 Summer Technology Program, which exposes them to technologies and careers in STEM-related fields.

🌟 Key Insights from EHRA Berlin 2024 🌟 One standout session featured Profs Ilan Goldenberg, Prof. Dr. David Duncker, Carsten Israel, and Breitenstein Alexander discussing the initial SCD risk in newly diagnosed HFrEF patients and the role of WCDs during early GRMT. 🔑 Key Points: • SCD is a leading cause of death in Western countries, highlighting the importance of early and accurate medication titration • The LVEF is crucial for SCD risk assessment • Ensuring proper patient selection for long-term ICD placement is vital • Early phase risk of SCD is significant, stressing the need for optimal beta-blocker dosage • The PROLONG-II study shows that 53% of patients improve LVEF within 180 days, potentially reducing the need for long-term ICDs • WCDs provide essential protection during high-risk periods 📹 https://ow.ly/1cRn50SBiNr #Cardiology #HeartFailure #SuddenCardiacDeath #WCD #GRMT #HeartHealth #ICD #MedicalResearch

Dr. Paul M. Zoll was a pioneer of external defibrillation and co-founder of ZOLL® Medical. Dr. Zoll’s research and innovations have helped save countless lives. Happy birthday, Dr. Zoll!

We are seeking a Director, Manufacturing Operations to lead our exceptional team at ZOLL Cardiac Management Solutions. As a highly motivated leader, you will set a high bar of achievement for yourself and the organization. Your role will involve directing production, service, and site materials operations, overseeing continuous improvement initiatives, and managing key support functions. Join us in driving excellence and innovation in the world of industrial engineering and electro-mechanical technologies. Reach out and apply today! bit.ly/3S1owl3

Heart failure hospitalizations are a heavy burden on patients, and physicians are striving to prevent them. ZOLL HFMS is a noninvasive way to monitor thoracic fluid level to help physicians intervene and prevent readmission – by as much as 38% in the first 90 days. bit.ly/3Ssw5Rl

ZOLL is a proud platinum sponsor of #NSN2024 and the Harvard University Strategic Sales program. We are one month away! If you’ll be there, too, plan to visit our booth and see how you can make a lifesaving difference with your career at ZOLL. Learn more about our sales roles: bit.ly/4cT9INq